Search

Joseph E Petroziello

from Throop, PA
Deceased
Get Report
Also known as:
Joseph M Petroziello
Phone and address:
447 Clark St, Scranton, PA 18512
(570) 489-2624
Related to:
Andrew C Catherman, 38James Edward Breitling, 77Joann P Collins, 57Jewell K Collins, 63Joann C Petroziello, 83Joan Petroziello, 83
Connected to:
Carl J Petroziello, 48Daniel P Petrozzo, 91Jennifer A Petrozza, 51Kayla L Petrozza, 33Louis Petrozza, 87Luke E Petrozza, 82Marisa N Petrozza, 41Mark C Petrozzi, 43Mark J Petrozzino, 63Teresa Petrozzino, 54

Joseph Petroziello Phones & Addresses

  • 447 Clark St, Throop, PA 18512 (570) 489-2624
  • Framingham, MA
  • Seattle, WA
  • Greenwich, CT
  • Philadelphia, PA
  • Bothell, WA

Work

Company: Scientific affairs - Voorhees, NJ Oct 2007 Position: Vp, head

Education

School / High School: University of Scranton- Scranton, PA Dec 1996 Specialities: M.A. in Clinical Chemistry

Resumes

Resumes

Joseph Petroziello Photo 1

Joseph Petroziello Philadelphia, PA

View page
Work:
Scientific Affairs
Voorhees, NJ
Oct 2007 to Oct 2008
VP, Head
Impact Communications Inc
New York, NY
Oct 2006 to Oct 2007
Associate Medical Director
PPSI Communications Inc
Stamford, CT
Feb 2005 to Oct 2006
Senior Medical Writer
IntraMed Group
New York, NY
Jun 2004 to Feb 2005
Senior Medical Writer
Seattle Genetics, Inc
Bothell, WA
Mar 2000 to Jun 2004
Senior Scientist, Head of mAb Discovery & Genomics
Genzyme Molecular Oncology
Framingham, MA
Jun 1997 to Mar 2000
Scientist
Genzyme Molecular Oncology
Framingham, MA
Jun 1996 to Jun 1997
Research Associate
Institute of Molecular Biology and Medicine
Scranton, PA
Jun 1994 to Jun 1996
Research Technician
University of Scranton
Scranton, PA
Sep 1992 to Jun 1994
Graduate Assistant
University of Scranton
San Antonio, TX
Jun 1993 to Sep 1993
Graduate Research Scientist
Education:
University of Scranton
Scranton, PA
Dec 1996
M.A. in Clinical Chemistry
University of Scranton
Scranton, PA
May 1992
B.S. in Biology

Publications

Us Patents

Cancer Associated Antigens, Sga-56M And Sga-56Mv, And Uses Thereof

View page
US Patent:
20060121476, Jun 8, 2006
Filed:
Sep 12, 2003
Appl. No.:
10/527572
Inventors:
Joseph Petroziello - Greenwich CT, US
Andrew Yamane - Snohomish WA, US
Alan Wahl - Mercer Island WA, US
Assignee:
SEATTLE GENETICS, INC. - BOTHELL WA
International Classification:
C12Q 1/68
G01N 33/574
US Classification:
435006000, 435007230
Abstract:
The present invention relates to nucleic and amino acid sequences of SGA-56M and variants thereof. An exemplary variant of SGA-56M is SGA-56Mv. SGA-56M and SGA-56Mv are differentially expressed in cancer tissues and transformed cell lines. In particular, these genes are expressed at elevated levels in breast cancer and lung cancer tissues and cell lines. The present invention is also directed to methods for diagnosing a cancer in a subject, determining the prognosis of a cancer patient, and/or monitoring the efficacy of a treatment regimen for a cancer patient. The present invention further provides methods for screening and identifying modulators (e.g., antagonists or agonists) of SGA-56M and/or SGA-56Mv expression and/or activity. Antagonists identified using the methods of the invention are useful for the treatment of cancer patients. Also encompassed by the present invention are compositions including nucleic and/or amino acid sequences of SGA-56M and SGA-56Mv or SGA-56M/SGA-56Mv modulators and a pharmaceutically acceptable carrier. Such compositions may be used to advantage to treat a subject with a cancer to ameliorate the symptoms of the cancer or reduce the cancer cell burden in the subject. These compositions may also be utilized to prevent or delay the onset of a cancer in a subject exhibiting a predisposition to developing a cancer.

Sga-1M, A Cancer Associated Antigen, And Uses Thereof

View page
US Patent:
20070128593, Jun 7, 2007
Filed:
Feb 3, 2003
Appl. No.:
10/503462
Inventors:
Joseph Petroziello - Kenmore WA, US
Alan Wahl - Mercer Island WA, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The present invention relates to a gene and gene product, SGA-1M that is differentially expressed in cancer tissues and cell lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-1M in cancer tissues and cell lines. Expression analysis has demonstrated overexpression of SGA-1M in breast cancer tissue and breast cancer derived cell lines, in ovarian cancer, skin cancer, a cancer of the lymphoid system, thyroid cancer, pancreatic cancer, stomach cancer, and lung cancer. The gene is expressed as a 1.95 kb mRNA. The full length cDNA comprises two open reading frames encoding polypeptides of 221 and 75 amino acids, respectively. Monitoring expression levels of SGA-1M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Reagents that target SGA-1M are useful for the treatment of cancer.

Expression Profiling In Non-Small Cell Lung Cancer

View page
US Patent:
20050272061, Dec 8, 2005
Filed:
Feb 22, 2005
Appl. No.:
11/063343
Inventors:
Joseph Petroziello - Greenwich CT, US
Paul Carter - Mercer Island WA, US
Assignee:
Seattle Genetics, Inc. - Bothell WA
International Classification:
C12Q001/68
G01N033/574
US Classification:
435006000, 435007230
Abstract:
The present invention relates to L genes and gene products that are differentially expressed in cancer tissues and cell lines. In a particular aspect of the invention, L genes and gene products are differentially expressed in lung cancer tissues and cell lines. In accordance with the present invention, L nucleic acid sequences, amino acid sequences and antibodies thereto, and methods of use thereof are presented. The L molecules and methods of the invention may be used to monitor expression levels of L genes, wherein the detection of aberrant levels of L molecules provides a positive diagnostic indicator of lung cancer and/or other L gene associated cancers and a useful prognostic indice of the state of such diseases. Also provided are compounds capable of modulating an L molecule mediated activity, which are identified using the L molecules and methods of the invention. Such L molecule modulating compounds may be used efficaciously to treat patients with lung cancer, or other L antigen positive cancers.
Control profile
Joseph E Petroziello from Throop, PADeceased Get Report